Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Axitinib (Inlyta™)

Last Updated: 08/27/20

Status: Currently a NF2 Clinical Trial

Chemical Structure, Axitinib
Axitinib, Inlyta, 319460-85-0, AG-013736, AG 013736,
UNII-C9LVQ0YUXG, AG013736, S1005_Selleck,
AG-013736, AG-13736
Trade Name:
Pharmaceutical Company
Legal Status:
℞ - Prescription/Under Clinical Trial
Treatment By:
Pill - Oral
Tumor Target:
Vestibular Schwannoma
Protein Target:
TKI and VEGF Inhibitor
NF2 Trials:
Recruiting Trial: NCT02129647


  • Drinking extra water or diluted fluids as well as avoiding fatty, fried, spicy, or highly sweet foods can help with many of the potential side effects.
  • Take Axitinib at night instead of the morning to prevent fatigue.

Other Known Uses

  • Breast Cancer
  • Renal Cell Carcinoma (RCC)
  • In Research for: Mesothelioma

Side Effects

  • High Blood Pressure/Nosebleeds
  • Diarrhea
  • Fatigue, Tiredness
  • Decrease in Appetite
  • Nausea, Vomiting
  • Hoarseness, Dry Thrroat
  • Skin Conditions, Dry Skin and Blisters
  • Constipation


  1. Petrilli, Alejandra M., et al. "Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells." Oncotarget 8.19 (2017): 31666. Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458238/ | DOI: doi:10.18632/oncotarget.15912
  2. Reveal, AI-Enabled Phenotypic Screens. "Clinically Relevant Drugs." (2012) Source: https://recursionpharma.com/wp-content/uploads/2017/09/AI-Enabled_Pheno-9_25_2017v24.pdf
  3. Meric-Bernstam, Funda, et al. "A decision support framework for genomically informed investigational cancer therapy." Journal of the National Cancer Institute 107.7 (2015): djv098. Source: https://academic.oup.com/jnci/article/107/7/djv098/913288 | DOI: 10.1093/jnci/djv098
  4. Karajannis, Matthias A., and Rosalie E. Ferner. "Neurofibromatosis-related tumors: emerging biology and therapies." Current opinion in pediatrics 27.1 (2015): 26. Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374132/ | DOI: 10.1097/MOP.0000000000000169
  5. Shaw, Adam. "Diagnosis and Management of Hereditary Meningioma and Vestibular Schwannoma." Rare Hereditary Cancers. Springer, Cham, 2016. 17-27. Source: https://link.springer.com/chapter/10.1007/978-3-319-29998-3_2 | DOI: 10.1007/978-3-319-29998-3_2
  6. Widemann, Brigitte C., and Scott R. Plotkin. "Consensus for NF clinical trials Recommendations of the REiNS collaboration (Supplement II)." (2016): S1-S3. Source: https://link.springer.com/chapter/10.1007/978-3-319-29998-3_2
What is NF2? | About Us | Treatment Options | Sitemap

Site Search

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2021